WordNet
- an antipsychotic drug (trade name Clozaril) used as a sedative and for treatment-resistant schizophrenia; know to have few side effects (同)Clozaril
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 統合失調症に対するクロザピン投与のガイドライン guidelines for prescribing clozapine in schizophrenia
- 2. Pediatric bipolar disorder: Overview of choosing treatment
- 3. Evaluation and management of treatment-resistant schizophrenia
- 4. 薬剤誘発性の好中球減少および無顆粒球症 drug induced neutropenia and agranulocytosis
- 5. 統合失調症に対する薬物療法：急性期および維持期の治療 pharmacotherapy for schizophrenia acute and maintenance phase treatment
English Journal
- Encapsulation of clozapine in polymeric nanocapsules and its biological effects.
- Łukasiewicz S1, Szczepanowicz K2, Podgórna K3, Błasiak E4, Majeed N5, Ogren SO6, Nowak W7, Warszyński P8, Dziedzicka-Wasylewska M9.
- Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2016 Apr 1;140:342-52. doi: 10.1016/j.colsurfb.2015.12.044. Epub 2016 Jan 6.
- Clozapine is an effective atypical antipsychotic drug that unfortunately exhibits poor oral bioavailability. Moreover, the clinical use of the compound is limited because of its numerous unfavorable and unsafe side effects. Therefore, the aim of the present study was the development of a new nanocar
- PMID 26774571
- Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?
- Chukhin E1,2, Terevnikov V2,3, Takala P4, Hakko H5, Putkonen H3,6, Räsänen P7, Stenberg JH1, Eronen M4, Joffe G1.
- Nordic journal of psychiatry.Nord J Psychiatry.2016 Apr;70(3):190-4. doi: 10.3109/08039488.2015.1074283. Epub 2015 Oct 8.
- BACKGROUND: Increased body weight and hyperlipidemia caused by antipsychotics may be associated with improved antipsychotic efficacy in schizophrenia. If this association has a causal interrelationship via a genuine pathophysiological mechanism, then body weight loss in antipsychotic-treated patient
- PMID 26450657
- Therapeutic equivalence of antipsychotics and antidepressants - A systematic review.
- Cessak G1, Rokita K2, Dąbrowska M3, Rozbicka KS3, Zaremba A3, Mirowska-Guzel D4, Bałkowiec-Iskra E5.
- Pharmacological reports : PR.Pharmacol Rep.2016 Apr;68(2):217-223. doi: 10.1016/j.pharep.2015.08.017. Epub 2015 Sep 11.
- The number of newly approved generic psychotropic drugs increases every year and, in many countries, their sales exceed the sales of brand-name counterparts. In order for any generic drug to receive an approval of regulatory authorities, its bioequivalence with the corresponding reference product mu
- PMID 26922520
Japanese Journal
- クロザピン (特集 統合失調症 : 病態解明と治療最前線) -- (統合失調症の臨床)
- 稲田 健,石郷岡 純
- 日本臨床 71(4), 678-683, 2013-04
- NAID 40019630607
Related Pictures
★リンクテーブル★
| リンク元 | 「クロザピン」 |
「クロザピン」
- first aid step1 2006 p.207,370
特徴
- 1990年にアメリカで最初に認可、発売された非定形型抗精神病薬。
- 錐体外路症状を惹起しない。プロラクチンの分泌を昂進させない。定型抗精神病薬に反応不良な症例にも有効
- 副作用のため、日本では臨床応用されていない。
薬理作用
- block 5-HT2 receptor and dopamine receptor
- 抗dopamine作用：弱い
- 抗D4受容体の選択的アゴニスト
副作用
- 無顆粒球症、起立性低血圧、洞性頻脈、hypersalivation、temperrature elevation、lowerd seizure threshold、便秘